Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in Castration-resistant Prostate Cancer

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2018 Dec 12

PMID 30533337

Citations 5

Authors

Mohamed Islam Delma

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a prevalent malignant disease. Castration-resistant prostate cancer (CRPC) is a poor prognosis form that develops upon resistance to first-line androgen deprivation therapy. Intensive research is ongoing to find efficient therapeutics for this refractory state. Actually, the combination of PI3K/Akt inhibitors with new-generation antiandrogens is among the most promising therapeutic schemes, although not yet at the optimal level. Metformin effects on prostate cancer, notably its therapeutic targets shared with antiandrogens and/or PI3K/Akt inhibitors, are reviewed in this article. From that, the hypothesis of PI3K/Akt-antiandrogens dual blockade optimization by metformin addition in CRPC will be deduced.

Citing Articles

Molecular Basis of Oncogenic PI3K Proteins.

Sheng Z, Beck P, Gabby M, Habte-Mariam S, Mitkos K Cancers (Basel). 2025; 17(1).

PMID: 39796708 PMC: 11720314. DOI: 10.3390/cancers17010077.

Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta.

Niu W, Zhang T, Ma L Sci Rep. 2023; 13(1):2459.

PMID: 36774376 PMC: 9922294. DOI: 10.1038/s41598-023-28475-6.

Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.

Catapano J, Luty M, Wrobel T, Pudelek M, Piwowarczyk K, Kedracka-Krok S Cell Mol Biol Lett. 2022; 27(1):100.

PMID: 36401206 PMC: 9673456. DOI: 10.1186/s11658-022-00400-1.

BK002 Induces miR-192-5p-Mediated Apoptosis in Castration-Resistant Prostate Cancer Cells Modulation of PI3K/CHOP.

Park M, Park H, Rahman M, Kim J, Park S, Cho Y Front Oncol. 2022; 12:791365.

PMID: 35321434 PMC: 8936126. DOI: 10.3389/fonc.2022.791365.

Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models.

Li Q, Xu K, Tian J, Lu Z, Pu J Oncol Lett. 2021; 22(4):715.

PMID: 34429755 PMC: 8371978. DOI: 10.3892/ol.2021.12976.

References

Saad F, Chi K, Finelli A, Hotte S, Izawa J, Kapoor A . The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015; 9(3-4):90-6. PMC: 4455631. DOI: 10.5489/cuaj.2526. View

Mulholland D, Tran L, Li Y, Cai H, Morim A, Wang S . Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011; 19(6):792-804. PMC: 3157296. DOI: 10.1016/j.ccr.2011.05.006. View

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

Foss M, Clement K . Metformin as a cause of late-onset chronic diarrhea. Pharmacotherapy. 2001; 21(11):1422-4. DOI: 10.1592/phco.21.17.1422.34430. View

Ketola K, Munuganti R, Davies A, Nip K, Bishop J, Zoubeidi A . Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. Clin Cancer Res. 2017; 23(22):6923-6933. DOI: 10.1158/1078-0432.CCR-17-0901. View

Wang Y, Yao B, Wang Y, Zhang M, Fu S, Gao H . Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. Int J Mol Med. 2014; 33(6):1514-22. DOI: 10.3892/ijmm.2014.1707. View

Xiang X, Saha A, Wen R, Ruderman N, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7. DOI: 10.1016/j.bbrc.2004.06.133. View

Liu Q, Tong D, Liu G, Xu J, Do K, Geary K . Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT. Cell Death Dis. 2017; 8(8):e3007. PMC: 5596596. DOI: 10.1038/cddis.2017.417. View

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

10.

Yung M, Chan D, Liu V, Yao K, Ngan H . Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013; 13:327. PMC: 3702529. DOI: 10.1186/1471-2407-13-327. View

11.

Khan K, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U . Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist. 2016; 21(7):855-60. PMC: 4943382. DOI: 10.1634/theoncologist.2015-0248. View

12.

Rothermundt C, Hayoz S, Templeton A, Winterhalder R, Strebel R, Bartschi D . Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014; 66(3):468-74. DOI: 10.1016/j.eururo.2013.12.057. View

13.

Queiroz E, Puukila S, Eichler R, Sampaio S, Forsyth H, Lees S . Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 2014; 9(5):e98207. PMC: 4032293. DOI: 10.1371/journal.pone.0098207. View

14.

Lynch R, Konicek B, McNulty A, Hanna K, Lewis J, Neubauer B . The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res. 2005; 3(3):163-9. DOI: 10.1158/1541-7786.MCR-04-0163. View

15.

Hemmings B, Restuccia D . PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012; 4(9):a011189. PMC: 3428770. DOI: 10.1101/cshperspect.a011189. View

16.

Massard C, Chi K, Castellano D, de Bono J, Gravis G, Dirix L . Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer. 2017; 76:36-44. DOI: 10.1016/j.ejca.2017.01.024. View

17.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

18.

Edlind M, Hsieh A . PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014; 16(3):378-86. PMC: 4023363. DOI: 10.4103/1008-682X.122876. View

19.

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

20.

Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A . Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology. 2014; 155(4):1207-21. PMC: 3959597. DOI: 10.1210/en.2013-1925. View